Search results
Results From The WOW.Com Content Network
Guaifenesin might act as an expectorant by increasing the volume and reducing the viscosity of secretions in the trachea and bronchi via stimulation of the gastric mucosa. . This stimulation leads to an increased parasympathetic activity in the respiratory tract via the so-called gastro-pulmonary reflex, although some in vitro studies suggested that it might also act directly on the ...
CVS Health is pulling from its shelves some cough-and-cold treatments that contain an ingredient that has been deemed ineffective by doctors and researchers. The drug store chain said it will ...
Guaifenesin/codeine is a fixed-dose combination cold medicine used for the treatment of cough. [1] It contains guaifenesin, an expectorant; and codeine, as the phosphate, an opioid antitussive. [1] It is taken by mouth. [1] It was approved for medical use in the United States in 2006. [1]
CVS’s stock price has dropped by more than 20% this year amid Medicare challenges within Aetna as medical costs increased, and on top of that, there was potential activist investor action.
That momentum helped fuel a record quarter for pharmacy sales during which CVS filled 432 million subscriptions, up 9% from Q3 2023, increasing its market share of scripts filled nationally to 27.3%.
It is commonly available in cough syrups and also as sustained-release tablets. Mucolytics can dissolve thick mucus and are usually used to help relieve respiratory difficulties. They do this by breaking down the chemical bonds between molecules in the mucus. [5] This in turn can lower the viscosity by altering the mucin-containing components.
The company was acquired by CVS Health in September 2014 and is operated as a separate brand and business of CVS, headquartered in Miami, Florida. The company mainly operates in Miami-Dade and Broward Counties and currently has 28 stores. Navarro Discount Pharmacies has a 17% market share in South Florida, ahead of Walgreens and CVS/pharmacy. [1]
On Wednesday, CVS Health Corp (NYSE:CVS) reported first-quarter sales of $88.4 billion, up 3.7% year over year, missing the consensus of $89.21 billion. This was largely due to strong growth in ...